Xentuzumab

• CAT Number: I042433
• CAS Number: 1417158-65-6
• Purity: ≥95%

Xentuzumab (Cat No.: I042433) is a humanized monoclonal antibody that targets insulin-like growth factor (IGF)-1 and IGF-2, blocking their interaction with the IGF-1 receptor (IGF-1R), which is involved in cell proliferation and survival. By inhibiting this pathway, xentuzumab aims to suppress tumor growth, particularly in cancers driven by IGF signaling, such as breast and lung cancers. It is being evaluated in clinical trials, including combination therapies with other anticancer agents. Xentuzumab represents a targeted approach to disrupting growth factor-mediated oncogenic signaling.

Reference

[1]. Weyer-Czernilofsky U, et al. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Mol Cancer Ther. 2020 Apr;19(4):1059-1069.
[Content Brief]